Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Biopub link?

<< Previous

Bullboard Posts

Next >>

Comment by Cookie2018on Apr 04, 2021 8:01pm

130 Views

Post# 32935630

RE:RE:Biopub link?

BitHorse @tanner @Algernon I believe you are misrepresenting Algergon Pharma, yes there was a iarticle and interview iwth BioPub, but it was Apr 1, 2020 not Apr 1, 2021 this is what I found,
if you can show me a link to prove your claim, then I would be glad to read it!!! Stop your ranting.....

https://www.facebook.com/AlgernonPharmaceuticals/videos/biopub-interview-with-algernon-pharmaceuticals-update-on-np-120-use-for-covid-19/548960985735252/

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec